This is due to studies showing PIM inhibition reducing expression of inhibitory molecules (e.g. PD-L1) on tumour cells and macrophages in the tumour microenvironment and a reported increase of stem-like properties in PIM-deficient T cells which could potentially drive longer lasting anti-cancer responses (Chatterjee et al., 2019; Xin et al., 2021; Clements and Warfel, 2022). This evidence concerns the gene CD274 and neoplasm.